M. de Boer
-
Geurts, S. M. E., Ibragimova, K. I. E., Ding, N., Meegdes, M., Erdkamp, F., Heijns, J. B., Tol, J., Vriens, B. E. P. J., Dercksen, M. W., Aaldering, K. N. A., Pepels, M. J. A. E., van de Winkel, L., Peters, N. A. J. B., van de Wouw, A. J., Maaskant, S. A. J. G., Teeuwen-Dedroog, N. J. A., van Nijnatten, T. J. A., de Boer, M., & Tjan-Heijnen, V. C. G. (2024). Time trends in real-world treatment patterns and survival in patients diagnosed with de novo HER2+?metastatic breast cancer: an analysis of the SONABRE registry. Breast Cancer Research and Treatment, 205(2), 287-302. https://doi.org/10.1007/s10549-023-07235-0Meer informative over deze publicatie
-
van Roozendaal, L. M., Vane, M. L. G., Colier, E., Strobbe, L. J. A., de Boer, M., Sonke, G., Van Maaren, M. C., & Smidt, M. L. (2024). Gene expression profiles in clinically T1-2N0 ER+HER2- breast cancer patients treated with breast-conserving therapy: their added value in case sentinel lymph node biopsy is not performed. Breast Cancer Research and Treatment, 203(1), 103-110. https://doi.org/10.1007/s10549-023-07128-2Meer informative over deze publicatie
-
Voorwerk, L., Isaeva, O. I. I., Horlings, H. M. M., Balduzzi, S., Chelushkin, M., Bakker, N. A. M., Champanhet, E., Garner, H., Sikorska, K., Loo, C. E. E., Kemper, I., Mandjes, I. A. M., de Maaker, M., van Geel, J. J. L., Boers, J., de Boer, M., Salgado, R., van Dongen, M. G. J., Sonke, G. S. S., ... Kok, M. (2023). PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial. Nature Cancer, 4(4), 535–549. https://doi.org/10.1038/s43018-023-00542-xMeer informative over deze publicatie
-
Rugo, H. S., Im, S.-A., Cardoso, F., Cortes, J., Curigliano, G., Musolino, A., Pegram, M. D., Bachelot, T., Wright, G. S., Saura, C., Escrivá-de-Romaní, S., De Laurentiis, M., Schwartz, G. N., Pluard, T. J., Ricci, F., Gwin, W. R., Levy, C., Brown-Glaberman, U., Ferrero, J.-M., ... SOPHIA Study Group (2023). Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial. Journal of Clinical Oncology, 41(2), 198-205. https://doi.org/10.1200/JCO.21.02937Meer informative over deze publicatie
-
de Mooij, C. M., van Nijnatten, T. J. A., Goorts, B., Kooreman, L. F. S., Raymakers, I. W. M., van Meijl, S. P. L., de Boer, M., Keymeulen, K. B. M. I., Wildberger, J. E., Mottaghy, F. M., Lobbes, M. B. I., & Smidt, M. L. (2023). Prediction of Primary Tumour and Axillary Lymph Node Response to Neoadjuvant Chemo(Targeted) Therapy with Dedicated Breast [18F]FDG PET/MRI in Breast Cancer. Cancers, 15(2), Article 401. https://doi.org/10.3390/cancers15020401Meer informative over deze publicatie
-
Hillege, L., Waelen, J., Ziemons, J., Aarnoutse, R., De Vos-Geelen, J., De Boer, M., Van Riet, Y., Vincent, J., Venema, K., Rensen, S., Simpson, J., Redinbo, M., Penders, J., & Smidt, M. (2022). Bacterial beta-glucuronidase activity in postmenopausal breast cancer patients: a pilot study. European Journal of Cancer, 175, S84-S84. https://doi.org/10.1016/S0959-8049(22)01578-7Meer informative over deze publicatie
-
Simons, J. M., van Nijnatten, T. J. A., van der Pol, C. C., van Diest, P. J., Jager, A., van Klaveren, D., Kam, B. L. R., Lobbes, M. B. I., de Boer, M., Verhoef, C., Sars, P. R. A., Heijmans, H. J., van Haaren, E. R. M., Vles, W. J., Contant, C. M. E., Menke-Pluijmers, M. B. E., Smit, L. H. M., Kelder, W., Boskamp, M., ... Smidt, M. L. (2022). Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla With Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer. JAMA Surgery, 157(11), 991-999. https://doi.org/10.1001/jamasurg.2022.3907Meer informative over deze publicatie
-
Aarnoutse, R., Ziemons, J., Hillege, L. E., de Vos-Geelen, J., de Boer, M., Bisschop, S. M. P., Vriens, B. E. P. J., Vincent, J., van de Wouw, A. J., Le, G. N., Venema, K., Rensen, S. S., Penders, J., & Smidt, M. L. (2022). Changes in intestinal microbiota in postmenopausal oestrogen receptor-positive breast cancer patients treated with (neo)adjuvant chemotherapy. npj Breast Cancer, 8(1), Article 89. https://doi.org/10.1038/s41523-022-00455-5Meer informative over deze publicatie
-
van Barele, M., Rieborn, A., Heemskerk-Gerritsen, B. A. M., Obdeijn, I.-M., Koppert, L. B., Loo, C. E., Tollenaar, R. A. E. M., Ausems, M. G. E. M., van de Beek, I., Berger, L. P. V., de Boer, M., van Hest, L. P., Kets, C. M., Rookus, M., Schmidt, M. K., Jager, A., Hooning, M. J., & HEBON (2022). Survival of BRCA1/BRCA2-associated pT1 breast cancer patients, a cohort study. Breast Cancer Research and Treatment, 194(1), 159-170. https://doi.org/10.1007/s10549-022-06608-1Meer informative over deze publicatie
-
Meegdes, M., Geurts, S. M. E., Erdkamp, F. L. G., Dercksen, M. W., Vriens, B. E. P. J., Aaldering, K. N. A., Pepels, M. J. A. E., Winkel, L. M. H., Teeuwen, N. J. A., Boer, M., & Tjan-Heijnen, V. C. G. (2022). The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2-advanced breast cancer patients: A study of the Dutch SONABRE Registry. International Journal of Cancer, 150(1), 124-131. https://doi.org/10.1002/ijc.33785Meer informative over deze publicatie
M. de Boer
Assistant Professor
Interne Geneeskunde
School for Cardiovascular Diseases
Fac. Health, Medicine and Life Sciences